Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus chemotherapy in recurrent or progressive metastatic urothelial cancer
2014-002009-40Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, paclitaxel, docetaxel and vinflunine in transitional cell carcinoma (TCC) and bladder cancer (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Aug 2014; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2014-002009-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002009-40.